Brief: Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain
31/03/2026 13:43
March 31 (Reuters) - Pelthos Therapeutics Inc PTHS.A: PELTHOS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A CLINICAL TRIAL OF CT2000 IN EYE PAIN PELTHOS THERAPEUTICS INC - RESULTS FROM PHASE 1B/2A CT2000 TRIAL ANTICIPATED AT END OF 2026 Source text: ID:nGNX9S8yvn Further company coverage: PTHS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pelthos Therapeutics
See all newsPelthos Therapeutics falls as co says will restate Q1 financial statements
Brief: Pelthos Therapeutics Financial Statements Should No Longer Be Relied Upon For Quarter Ended March 31- SEC Filing
Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Brief: Pelthos Therapeutics Announces CFO Transition
Brief: Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain